Entering text into the input field will update the search result below

FDA clears Profound Medical's TULSA-PRO for ablation of prostate tissue

  • Profound Medical (OTCQX:PRFMF) has received 510(k) clearance from the FDA to market TULSA-PRO for ablation of prostate tissue.
  • TULSA-PRO is a transurethral prostate tissue ablation system that combines Magnetic Resonance Imaging with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.
  • U.S. commercial launch will start next quarter.

Recommended For You

Related Stocks

SymbolLast Price% Chg
PRFMF--
Profound Medical Corp.